N-Terminal Acetylation

N-terminal acetylation replaces one hydrogen on the alpha-amino group at the start of a chain with an acetyl group. The change is small in mass terms, 42 daltons, but it is large in behaviour. The free amine is basic and carries a positive charge at physiological pH; the acetamide it becomes is neutral. That lowers the net charge by one, shifts the isoelectric point downward, and removes the unsubstituted primary amine that aminopeptidases require in order to begin chewing the chain in from the front.

Nature uses the modification. Alpha-melanocyte-stimulating hormone circulates acetylated at the N-terminus and amidated at the C-terminus, and both caps are needed for full potency at melanocortin receptors. Synthetic chemistry uses it constantly, and the cosmetic ingredient nomenclature makes it visible: names beginning with acetyl, such as acetyl hexapeptide-8, are declaring exactly this cap. In solid-phase synthesis it is trivial to install, since the terminal amine is already exposed on the resin at the end of the assembly.

The decision it drives is whether to spend a charge to buy stability. Capping the front end typically extends survival in serum and pairs well with C-terminal amidation, which does the same job at the other end. But the free amine is sometimes part of the pharmacophore rather than a liability, and blocking it can abolish activity outright, so acetylation is a design choice to be tested rather than a default upgrade.

Two misreadings recur. The first is treating the acetyl prefix as evidence of efficacy; it describes a chemical cap, not a demonstrated effect. The second is confusing acetylation with an acetate counterion. One is a covalent bond that changes the molecule and its measured mass; the other is a salt that dissociates the moment the powder dissolves.